TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04722263

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 15 Gy in 3 fractions
Study: NCT04539262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV)
Description: Administered as an aerosolized solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV)
Description: Administered as an aerosolized solution
Study: NCT03837197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kidney-Hypothermic oxygenated
Description: Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys.
Study: NCT00515541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza
Description: First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
Study: NCT00006243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tyrosinase peptide
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1:27-35 peptide vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1:27-35 peptide vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1:27-35 peptide vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02447744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based intervention
Description: The intervention is an 8-week structured mindfulness based behavioral intervention program that teaches mindfulness meditation, mindful yoga and psychological knowledge about stress.
Study: NCT04539262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV)
Description: Administered as an aerosolized solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV)
Description: Administered as an aerosolized solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir (RDV)
Description: Administered as an aerosolized solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an aerosolized solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an aerosolized solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an aerosolized solution
Study: NCT02447744

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness based intervention
Description: The intervention is an 8-week structured mindfulness based behavioral intervention program that teaches mindfulness meditation, mindful yoga and psychological knowledge about stress.
Study: NCT04181749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin and atorvastatin
Description: Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
Study: NCT02724930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced facilitation of COPES
Description: Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
Study: NCT04539262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an aerosolized solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an aerosolized solution
Study: NCT01008332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toleromune HDM
Description: ToleroMune HDM dose 1x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toleromune HDM
Description: ToleroMune HDM dose 1x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toleromune HDM
Description: ToleroMune HDM dose 1x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toleromune HDM
Description: ToleroMune HDM dose 1x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toleromune HDM
Description: ToleroMune HDM dose 1x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 4 weeks apart
Study: NCT03778827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Center-Based Pivotal Response Treatment (PRT-C)
Description: Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of weekly individual parent training sessions and center-based therapy for a total of 13 weekly treatment hours.
Study: NCT03659526

Intervention type: DIAGNOSTIC_TEST
Intervention: Deformation imaging
Description: Deformation parameters derived using myocardial velocity imaging or speckle tracking

Intervention type: DIAGNOSTIC_TEST
Intervention: Deformation imaging
Description: Deformation parameters derived using myocardial velocity imaging or speckle tracking
Study: NCT00092222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV day 1, shall be administered prior to Doxil injection. When combined with EPOCH chemotherapy, Rituximab will be given on days 1 and 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV day 1, shall be administered prior to Doxil injection. When combined with EPOCH chemotherapy, Rituximab will be given on days 1 and 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Cycle 1: Zidovudine 600 mg PO QID x 7-21 days in outpatient setting;600 mg PO q6hours x 7-21 (Intravenous zidovudine 300 mg q 6 hours may be substituted) days for inpatients; Cycle 2 and beyond: 600 mg PO QID x 7 days in outpatient setting; 600 mg PO q 6 hours x 7 days (300 mg q 6 hours may be substituted)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Cycle 1: Zidovudine 600 mg PO QID x 7-21 days in outpatient setting;600 mg PO q6hours x 7-21 (Intravenous zidovudine 300 mg q 6 hours may be substituted) days for inpatients; Cycle 2 and beyond: 600 mg PO QID x 7 days in outpatient setting; 600 mg PO q 6 hours x 7 days (300 mg q 6 hours may be substituted)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Doxorubicin
Description: 21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
Study: NCT02837861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine Nutritional Support plus supplemental IV amino acids
Description: Enteral nutrition as tolerated Plus supplemental IV AA infusion to meet the target of approximately 1.5-2.0gm protein/kg/day total starting within 24 hours of injury for 5 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Nutritional Support
Description: Enteral nutrition as tolerated.
Study: NCT03820908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisantrene
Description: The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
Study: NCT02725736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atosiban
Description: After random allocation to a treatment group, women will receive Atosiban as follows:~Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: After random allocation to a treatment group, women will receive Nifedipine as follows:~Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours.
Study: NCT03710694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAV132
Description: DAV132:~* Dosage: 15 g/day activated charcoal (22.5 g/day DAV132)~* Route: Oral~* Duration: duration of fluoroquinolone treatment + 2 days~DAV132 is regulated as a medical device in Europe and as a drug in the United States of America.
Study: NCT00591162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Duel Energy X-Ray Absorptiometry (DEXA)
Description: DEXA before discharge from acute admission and again one year post burn.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Biopsy
Description: Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
Study: NCT03127462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led educational intervention
Description: Patients in the intervention group will receive an individual face-to-face conversation with a duration of 45 min. All patients will have access to telephone counselling by their primary nurse when needed and able to arrange a new face-to-face conversation. After 4-6 weeks the face-to-face the nurse will of conversation reach out to the patient by phone to follow up on the earlier conversation. Three months after the face-to-face conversation the nurse will offer the patient a closing face-to-face conversation of 15 min at the same time where the patient has a doctor appointment at the department. Those who are in the control group will continue standard care and not receive any conversation and be used as the control group.
Study: NCT02635867

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Pulp capping-Resin-modified calcium silicate - TheraCal
Description: Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Pulp capping-Calcium hydroxide - Dycal
Description: Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Pulp capping-Resin-based dentin bonding agent
Description: Use of a dental restorative protocol using resin-based dentin bonding system only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp capping-Resin-modified calcium silicate - TheraCal
Description: Use of a dental restorative protocol using Resin-modified calcium silicate - TheraCal pulp capping restorative material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Pulp capping-Calcium hydroxide - Dycal
Description: \\Use of a dental restorative protocol using Calcium hydroxide - Dycal pulp capping restorative material
Study: NCT04207008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iBDecide Decision Support Application
Description: The iBDecide app provides an electronic tools to learn more about UC, track symptoms, create a nutrition diary, enter reminders for medication and clinic visits, as well as learn more about treatment options and compare UC medications.
Study: NCT01712191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NUsurface Meniscus Implant
Study: NCT00935662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8329
Description: Oral solution, single ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution, placebo
Study: NCT03885609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ToothWave
Description: RF-utilizing powered toothbrush for teeth whitening

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: powered toothbrush
Description: regular powered toothbrush with no RF
Study: NCT02169960

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smart, Positive, Active, Realistic X-factor thoughts (SPARX)
Description: Cognitive Behavioral Therapy based online intervention for depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smart, Positive, Active, Realistic X-factor thoughts (SPARX)
Description: Cognitive Behavioral Therapy based online intervention for depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breaking Free
Description: Online based intervention for Drug and Alcohol Use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breaking Free
Description: Online based intervention for Drug and Alcohol Use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: This Way Up
Description: Cognitive Behavioral Therapy online intervention for Depression and Anxiety

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: This Way Up
Description: Cognitive Behavioral Therapy online intervention for Depression and Anxiety

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resiliency Training
Description: Op Volle Kracht (OVK)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resiliency Training
Description: Op Volle Kracht (OVK)
Study: NCT02668692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 80185 gel
Description: calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovobet ® ointment
Description: calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
Study: NCT04171063

Intervention type: DEVICE
Group type: OTHER
Intervention: Thoracic compressor
Description: The intervention is the use of the thoracic compressor for the conservative treatment of pectus carinatum
Study: NCT00534924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit C

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Study: NCT00748332

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortimel Extra®
Description: 2 bottles (600 kcal, 40 g proteins) per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortimel Care®
Description: Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
Study: NCT01500265

Intervention type: BIOLOGICAL
Intervention: plasma and urine samples, sample with ADN
Description: plasma and urine samples every three months Sample with ADN at baseline

Intervention type: BIOLOGICAL
Intervention: plasma and urine samples, sample with ADN
Description: plasma and urine samples every three months Sample with ADN at baseline

Intervention type: BIOLOGICAL
Intervention: plasma and urine samples, sample with ADN
Description: plasma and urine samples every three months Sample with ADN at baseline
Study: NCT04299256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benson relaxation combined with music therapy
Description: In the first interview, the patient information delivered a training booklet explaining the definition, purpose, benefits and application techniques of BRT and music therapy to the patients in the intervention group. After patients reviewed the details in the training booklet, a weekly schedule was planned for each patient based on their hemodialysis days. For the initiation of the intervention, patients were invited to the hemodialysis unit at the hospital 45 min prior to their hemodialysis sessions. All the participants wore black eye patches to provide a dim environment and to focus better on their breath and the music piece. Then, the patients information opened the music piece and gave Benson Relaxation Technique comments in a slightly lower voice. Each session lasted for 20 min, and the music piece was switched off as Benson Relaxation Technique ended. The music piece used in the study was Daniel Kobelco's non-verbal classical song.
Study: NCT03286881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief individual psychotherapy
Description: Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief group psychotherapy
Description: Group brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in primary care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined intervention
Description: Traditional psychotherapy and medication provided by a clinical psychologist and a psychiatrist in secondary care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimum psychological intervention
Description: Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment
Description: Medication provided by a general practitioner.
Study: NCT02092168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Study: NCT02421146

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation - Sham
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation - Sham
Description: Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.